Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms (TADE)

This study has been completed.
Sponsor:
Collaborator:
St George Hospital, Australia
Information provided by (Responsible Party):
Howard Gurney, Western Sydney Local Health District
ClinicalTrials.gov Identifier:
NCT01075802
First received: February 24, 2010
Last updated: May 3, 2013
Last verified: May 2013
  Purpose

Tamoxifen is an important drug for the treatment of breast cancer. Used adjuvantly after operation in early breast cancer, tamoxifen reduces annual recurrence rate by half and cancer death by one third. Used preventatively it also reduces the risk of breast cancer by 50% in women at high risk for developing the disease Tamoxifen needs to be activated in the body to an active form called endoxifen, mainly by the enzyme called CYP2D6. Patients have variable capability to activate tamoxifen due to variable function of this enzyme. Studies showed clear correlation of specific genetic variant of CYP2D6 with endoxifen blood levels. It is estimated that up to 25% Caucasian population have reduced or even absent CYP2D6 function. More recently, there were studies that showed the correlation with genetic variant of CYP2D6 and breast cancer relapse in early breast cancer patients treated with tamoxifen. Food and Drug Authority (FDA) in America and recommended checking CYP2D6 genotype in patients receiving tamoxifen treatment, but they did not specify how to interpret the genotype results and what kind actions to take in patient with adverse genotype. The aim of the investigators study is to see if increasing tamoxifen in patients with genetic polymorphism of CYP2D6 will increase endoxifen level to the same range of most patients who have wild type (normal functional)CYP2D6.


Condition Intervention
Breast Cancer
CYP2D6 Polymorphism
Drug: Tamoxifen

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: A Multi-Centre Study of Tamoxifen Dose Escalation Study in Breast Cancer Patients With CYP2D6 Polymorphisms

Resource links provided by NLM:


Further study details as provided by Western Sydney Local Health District:

Primary Outcome Measures:
  • Effects of genotype of CYP2D on plasma and serum concentration of tamoxifen and its metabolites, with consequent recommendation for dosage adjustment [ Time Frame: dose escalation over 40 weeks ] [ Designated as safety issue: No ]
  • To test whether Tamoxifen dose escalation in patients with genetic polymorphism of CYP2D6 will increase endoxifen blood levels to a target level [ Time Frame: Dose escalation over 40 weeks ] [ Designated as safety issue: No ]
  • Correlate tamoxifen and its metabolites concentration with tamoxifen side effects [ Time Frame: dose escalation over 40 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 121
Study Start Date: March 2010
Study Completion Date: December 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tamoxifen
Dose escalation of tamoxifen in patients with low endoxifen levels
Drug: Tamoxifen
Dose escalation

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months
  • Histologically or cytologically confirmed early, locally advanced or metastatic breast cancer
  • Oestrogen receptor positive
  • About to start tamoxifen treatment or already on tamoxifen 20mg daily
  • Adequate hepatic and renal function

Exclusion Criteria:

  • Concurrent chemotherapy or radiotherapy
  • Treatment with medications that may alter cytochrome P450 (CYP450)3A4/5 and CYP2D6 activities
  • History of thrombosis
  • History of non-compliance with previous or current treatment;
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01075802

Locations
Australia, New South Wales
St George Hospital
Sydney, New South Wales, Australia
Westmead Cancer Care Centre
Westmead, New South Wales, Australia, 2145
Sponsors and Collaborators
Western Sydney Local Health District
St George Hospital, Australia
Investigators
Principal Investigator: Howard Gurney, MBBS,FRACP South West Sydney Local Health District
  More Information

No publications provided

Responsible Party: Howard Gurney, A/Prof Howard Gurney, Western Sydney Local Health District
ClinicalTrials.gov Identifier: NCT01075802     History of Changes
Other Study ID Numbers: TADE study
Study First Received: February 24, 2010
Last Updated: May 3, 2013
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Western Sydney Local Health District:
Breast cancer
Tamoxifen
Endoxifen
polymorphism of CYP2D6

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Tamoxifen
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Bone Density Conservation Agents
Estrogen Antagonists

ClinicalTrials.gov processed this record on July 23, 2014